

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
--	------------------	--------------------------	---	-----------------------

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Alitretinoin for the treatment of severe chronic hand eczema

Issue date: October 2008

<p>1.</p>	<p><i>Basilea Pharmaceuticals Ltd</i></p>	<p><i>Ligand are not the manufacturer of oral alitretinoin but are the manufacturer of topical alitretinoin used in the treatment of Kaposis sarcoma. Because the invitation to comment on draft scope was sent in error to Ligand instead of Basilea, Basilea did not become aware of the draft scope until the 25th April.</i></p> <p><i>Chronic eczema confined to the hands is not a disease of childhood-a single case has been reported in the literature, hence the paediatric interest groups; Action for Sick Children, Wellchild, Royal College of Paediatrics should be removed from the list</i></p> <p><i>Manufacturers of agents not used in the treatment of CHE should be removed from the list. Basilea would recommend the removal of: Allergan, Crookes, Galderma, Janssen-Cilag, Serono, Stiefel, and Wyeth. In view of the suggested inclusion of PUVA as a comparator, the British Photodermatology Group may be an appropriate consultee to include.</i></p> <p><i>The Cochrane Skin Group are a highly relevant stakeholder as it is our understanding that they have recently completed a systematic review of therapy for CHE</i></p>	<p><i>To be discussed at meeting</i></p>	
<p>National Institute for Health and Clinical Excellence</p>	<p>Response to comments on the provision of information to the UK's National Institute for Health and Clinical Excellence</p> <p>Issue date: October 2008</p>	<p>The British Association of Dermatologists also have a guideline group and a subgroup; the British Contact Dermatitis Society that may be</p>	<p>(pre-referral) for the appraisal of Alitretinoin for the treatment of severe chronic hand eczema</p>	

	<p><i>Continued</i></p>	<p><i>Input from a UK representative of the European Contact Dermatitis Research Group, shortly to issue guidelines on the classification of CHE may be desirable.</i></p> <p><i>The British Association of Dermatology also have a guideline group and a subgroup; the British Contact Dermatitis Society that may be a relevant stakeholders for comment</i></p>	<p><i>To be discussed at meeting</i></p>	
--	-------------------------	--	--	--

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Alitretinoin for the treatment of severe chronic hand eczema

Issue date: October 2008

2.	<i>Centre of Evidence-Based Dermatology</i>	<i>Under 'Professional Groups', please add 'British Contact Dermatitis Society' Under 'General', please add 'Association of National Health Occupational Physicians'</i>	<i>To be discussed at meeting</i>	
----	---	--	-----------------------------------	--

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Alitretinoin for the treatment of severe chronic hand eczema

Issue date: October 2008